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Dear Editor,
Paraneoplastic dermatomyositis is a distinct clini-
cal variant of dermatomyositis (DM) in which the typi-
cal cutaneous features and muscle weakness appear 
before, simultaneously, or after the diagnosis of an 
internal malignancy. It occurs in approximately one-
third of patients with DM, predominantly adults, after 
the age of 40 (1). Different neoplasms have been de-
scribed in association with DM, the most common of 
which are lung, breast, ovarian, gastrointestinal, pros-
tate, and bladder cancers. The gender distribution of 
cancer type corresponds roughly to that of the gen-
eral population (1,2).
We report the case of a 58-year-old man who pre-
sented with facial heliotrope erythema, periorbital 
edema, Gottron’s papules over the interphalangeal 
and metacarpophalangeal joints, and Gottron’s sign 
on the elbows (Figure 1). The patient also exhibited 
some less frequent skin signs of DM, such as shawl 
sign on the upper back and shoulders and V-sign 
on the neck and chest. Apart from the rash, he com-
plained of weight loss, adynamia, dysphagia, cough, 
and scant expectoration, which he reported experi-
encing over a 3-month period. The muscle involve-
ment consisted of proximal muscle weakness and 
had appeared a month after the skin rash. 
The histology of the skin lesion revealed epider-
mal atrophy, vacuolar degeneration of the basal kera-
tinocytes, and perivascular and periadnexal lympho-
cytic infiltrate in the upper dermis (Figure 2). Labo-
ratory examination found increased creatine kinase 
(2822 U/L) and liver enzymes, anemia, and leukocyto-
sis. Screening for antinuclear antibodies and anti-Jo1 
autoantibodies were both negative. The diagnosis of 
trichinosis was excluded via serologic examination. 
The impaired general condition of the patient led 
to a prompt paraneoplastic screening. Abdominal 
sonography detected hepatomegaly. Computed to-
mography (CT) of the abdomen and pelvis visualized 
a mass in the distal part of the esophagus, narrowed 
lumen of the gastric cardia, enlarged gastric lymph 
nodes, lung and liver metastases, and ascites (Figure 
3). The diagnosis of paraneoplastic DM in association 
with an advanced, metastatic, primary gastric carci-
noma was established. Palliative surgery and chemo-
therapy were proposed to the patient, but he refused 
both. A systemic therapy with methylprednisolone 
Figure 1. (A) Heliotrope erythema, periorbital edema, ery-
thematous to livid discoloration of the face, and scaly ery-
thema of the scalp; (B) Shawl sign on the upper back and 
shoulders; (C) Gottron’s papules over the interphalangeal 




60 mg/daily and azathioprine 100 mg/daily was initi-
ated, aiming to alleviate the progressively worsening 
muscle weakness, but proved ineffective. The patient 
died two months later of combined respiratory and 
heart failure. 
There are multiple prediction factors, such as cu-
taneous signs, laboratory data, and disease progres-
sion, which may direct the physician towards the pos-
sibility of paraneoplastic DM. 
Some atypical cutaneous lesions, such as cuta-
neous necrosis or vasculitis, hyperkeratotic follicular 
papules, vesiculo-bullous lesions, and flagellate ery-
thema, are seen more frequently in cancer-associated 
DM (3,4). None of these were present in our patient. 
Pruritus is also described as a paraneoplastic sign (5). 
Some authors consider the increased erythrocyte 
sedimentation rate and C-reactive protein to be of 
predictive value for malignancy.
Myositis-specific autoantibodies anti-TIF1-γ and 
anti-NXP-2, among the numerous novel serological 
markers for DM, are clearly associated with the pres-
ence of neoplasia (6,7). Unfortunately, we were un-
able to test for those autoantibodies.
The symptom of dysphagia is a hallmark of para-
neoplastic dermatomyositis and usually represents a 
manifestation of muscle weakness (8). In our case, it 
was rather a reflection of the endoluminal tumor, al-
though it may also be a combination of both factors. 
In their study, Bowerman et al. investigated the 
risk of cancer development in different DM subtypes 
(9). They included 201 patients with adult-onset DM, 
142 of with classic DM and 59 with the clinically amyo-
pathic type. The estimated prevalence of malignancy-
associated classic and clinically amyopathic DM were 
9.9% and 1.7%, respectively. The authors concluded 
that older age and classic DM represent independent 
risk factors for malignancy-associated DM within 2 
years of disease onset.
Given that early diagnosis significantly impacts 
prognosis in patients with cancer-associated DM, re-
cent studies support blind screening for internal ma-
lignancy (10). Leatham et al. performed a retrospec-
tive analysis of 400 patients with DM, finding a total 
of 53 cancers in 48 patients (some of the patients had 
two separate neoplasms). Among the group of para-
neoplastic DM cases, 17 cancers were diagnosed via 
purely blind screening in patients with a lack of con-
cerning history or physical examination. The authors 
Figure 3. Abdominal CT scan visualizing a mass in the distal part of esophagus, narrowed lumen of the gastric cardia, 
enlarged gastric lymph nodes, and lung and liver metastases.
Figure 2. Hematoxylin and eosin staining (×200). Epider-
mal atrophy, vacuolar degeneration of the basal keratino-
cytes, perivascular and periadnexal lymphocytic infiltrate in 
the upper dermis.
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claimed that the most informative tests were mam-
mography and CT scanning. The above-mentioned 
predictive factors for paraneoplastic DM represent 
a useful tool for the clinician. Although it is gener-
ally accepted that patients with DM should undergo 
some type of cancer screening, there is no consensus 
regarding methods or frequency. New data suggest 
that blind screening in asymptomatic patients might 
be of great importance for early diagnosis and treat-
ment of patients with cancer-associated DM. 
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